Stroke-induced lipocalin-2-expressing red pulp macrophages reprogram peripheral immunity
Preprint
Abstract
Acute ischemic stroke (AIS) induces profound systemic immune alterations that contribute to infection susceptibility. Here, we identify lipocalin-2 (LCN-2) as a rapidly induced and conserved regulator of stroke-associated immunosuppression. Using 3-MACE-Seq, cytokine profiling, and immunofluorescence in C57BL/6J mice subjected to transient middle cerebral artery occlusion (tMCAO), we show that LCN-2 is strongly upregulated in splenic red pulp macrophages (RPMs) within 24 hours and again 7 days post-tMCAO. LCN-2-expressing RPMs form immunological synapses with CD3+ T cells, thereby impacting T cell trafficking. Recombinant LCN-2 directly reprogrammed T cells and monocytes toward hyporesponsive, tolerogenic phenotypes by suppressing inflammatory cytokines, impairing chemotaxis, enhancing phagocytosis, and uncoupling oxidative burst. Human spleens likewise displayed LCN-2-expressing CD68+ RPMs, and LCN-2 preconditioning of monocytes reproduced reduced HLA-DR, CD80, CD206, and ROS with increased uptake of E. coli bioparticles. These findings identify LCN-2 signaling as a central or-chestrator of stroke-induced peripheral immunoreprogramming and a potential therapeutic target to mitigate post-stroke immunodepression.Keywords
Funding Information
- German Research Foundation (SFB1039-TPB08)
- German Research Foundation (SU 1360/1-1)
- Uniscientia Stiftung Vaduz
- Frankfurt-Forschungs-Foerderung (Patenschaftsmodell)
- Federal Ministry of Education and Research, Germany (national Translational Tandem Program for Gene- and Cell-based Therapies)
This publication has 126 references indexed in Scilit:
- Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5PAtherosclerosis, 2023
- Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic strokeBrain and Behavior, 2023
- Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysisJAMA, 2016
- Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune ExpansionTranslational Stroke Research, 2015
- Differential effects of sympathetic nervous system and hypothalamic–pituitary–adrenal axis on systemic immune cells after severe experimental strokeBrain, Behavior, and Immunity, 2014
- A Transient Decrease in Spleen Size Following Stroke Corresponds to Splenocyte Release into Systemic CirculationJournal of Neuroimmune Pharmacology, 2012
- Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosisGlia, 2012
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- Eukaryotic elongation factor‐2 (eEF2): its regulation and peptide chain elongationCell Biochemistry and Function, 2011
- The spleen contributes to stroke‐induced neurodegenerationJournal of Neuroscience Research, 2008